Shares of Genetron Holdings Ltd. (GTH) are rising over 24%, after the company announced an exclusive strategic partnership agreement with Chia Tai Tianqing Pharmaceutical Group Co. Ltd., a subsidiary of Sino Biopharmaceutical Ltd., for HCCscreen, Genetron Health's blood-based early screening test for hepatocellular carcinoma or HCC in China.
As per the deal, the companies would work together exclusively to co-market and co-promote HCCscreen in the hospital market, covering designated territories in China.
The stock has been trading in the range of $9.03 - $17.71 for the past one year, and is currently trading at $17.10, up $3.39 or 24.72%, with trading volume of 483K versus an average volume of 316K shares.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.